RESEARCH ARTICLE

Comparative efficacy and safety of caffeine citrate and aminophylline in treating apnea of prematurity: A systematic review and meta-analysis

Yiqun Miao, Yun Zhou, Shuliang Zhao, Wenwen Liu, Aihua Wang, Yuanyuan Zhang, Yanan Li, Huimin Jiang

School of Nursing, Weifang Medical University, Weifang, Shandong Province, China

☯ These authors contributed equally to this work.
* wangaihua64@163.com

Abstract

Background
Methylxanthine, including caffeine citrate and aminophylline, is the most common pharmacologic treatment for apnea of prematurity. However, due to the lack of high-quality evidence, there are no clear recommendations or guidelines on how to choose between caffeine and aminophylline.

Objective
This meta-analysis aimed to assess the comparative efficacy and safety of caffeine and aminophylline for apnea of prematurity, and provide reliable evidence for clinical medication in the treatment for apnea of prematurity.

Methods
PubMed, Scopus, Embase, EBSCO, Web of Science, and Cochrane databases were systematically searched from May 1975 to June 2022.

Results
Ten studies including a total of 923 preterm infants were evaluated. Our results showed that there was no significant difference in the effective rate of 1-3 days between caffeine and aminophylline (OR 1.05, 95%CI: 0.40–2.74, \(P = 0.914\)). However, for side effects such as tachycardia (OR 0.22, 95%CI: 0.13–0.37, \(P < 0.001\)) and feeding intolerance (OR 0.40, 95%CI: 0.23–0.70, \(P = 0.001\)), the incidence rate was lower in the caffeine group compared with the aminophylline group. No significant difference was found in hyperglycemia (OR 0.45, 95%CI: 0.19–1.05, \(P = 0.064\)).
Conclusion
This meta-analysis reveals that caffeine citrate and aminophylline have similar therapeutic effectiveness on respiratory function, but caffeine has fewer side effects and should be considered first for treatment.

Introduction
Apnea of prematurity (AOP) is a common phenomenon in premature infants, which is defined as the temporary cessation of breathing and may be accompanied by bradycardia and desaturations [1]. This instability of the cardiovascular and respiratory system may be the result of infants’ immature respiratory drive and imbalance of sympathetic and parasympathetic outputs [2]. The incidence of AOP is negatively related to gestational age, with 85% of infants less than 34 weeks of gestational age developing AOP and almost all infants less than 30 weeks of gestational age or less than 1000g of birth weight developing AOP [3]. If AOP persists or is poorly controlled, it can lead to the development of bronchopulmonary dysplasia and retinopathy of preterm infants, and even increase infant mortality [4]. Therefore, considering the potential short-term and long-term effects of apnea, early and effective clinical intervention is vital.

Although many options exist for treating apnea in preterm infants, there is no clear “first-line” approach or gold standard of care. At present, methylxanthine therapy is the mainstay of treatment for apnea, including caffeine and aminophylline/theophylline [5]. Despite its widespread use, there is still considerable uncertainty in the efficacy and safety of treating apnea of prematurity [6]. Several studies have proved that caffeine has better therapeutic efficacy with fewer adverse effects, is more reliably absorbed when administered enterally, and is gradually replacing aminophylline as the primary drug for AOP [7, 8]. However, a previous study assessed that the positive effects of caffeine on premature infants’ respiratory may be offset by its negative effects on the central nervous system [9]. Recent studies have also shown that caffeine citrate increased the metabolism and oxygen consumption, which could lead to irritability in children [10, 11]. And caffeine citrate is expensive, there are often shortages of the drug in some parts of the world, aminophylline is still the most widely used medicine especially in developing countries [12]. Therefore, there are still some controversies surrounding the choice between caffeine citrate and aminophylline for apnea of prematurity.

Due to the limited hepatic, renal, and respiratory functions of the preterm infants, there is great concern about choosing the one with quick effects, small side effects and low toxicity in the course of treatment. Therefore, this meta-analysis focuses on reliable data regarding the efficacy and safety of caffeine and aminophylline for apnea of prematurity, aiming to provide effective evidence-based medication guidelines for clinicians.

Materials and methods
Systematic search and strategy
Our research team performed the meta-analysis based on the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) [13]. PRISMA checklist was shown in SI Table. We searched Embase, PubMed, Web of Science, EBSCO, Cochrane, and Scopus databases from May 1975 to June 2022 for all relevant articles. The search was conducted based on the 5 elements of the PICOS model, 2 of which (population, intervention/
exposure) were addressed in the search strategy (S2 Table). The search strategy combined two areas as MeSH terms, keywords, and text words using Boolean operators: ("Caffeine Citrate" OR "Caffeine" OR "Citrates") AND ("Theophylline" OR "Aminophylline" OR "Diaphylline" OR "Aminophyllinum") AND ("Apnea" OR "Apnoea") AND ("Preterm infants" OR "Infant, Premature" OR "Premature Infant" OR "Infants, Preterm" OR "Neonatal Prematurity").

Inclusion and exclusion criteria
In this meta-analysis, the research needed to meet the following inclusion criteria:

1. Infants born <37 weeks of gestation and diagnosed with apnea (Respiratory arrest for ≥20 s, may be accompanied by bradycardia (heart rate <100 bpm) or oxygen desaturation (SpO2 <80%), and that occurred more than 12 h after birth.);
2. Randomized controlled studies and observational studies;
3. A group exposed to caffeine citrate therapy (exposure group), a group exposed to aminophylline therapy (control group), and there was a comparison among the two groups;
4. At least one of the parameters was included in the outcome measures: the effective rate of 1-3 days, sinus tachycardia, feeding intolerance, hyperglycemia, total adverse effects. The effective of 1-3 days was defined as 50% or greater reduction in apnea episodes within 72 h and <3 times/day after administrating the drugs [14]; Sinus tachycardia is defined as the heart rate persistence >160 bpm or the heart rate > 20% of the baseline heart rate after medication in infants. The diagnosis of feeding intolerance and hyperglycemia relies on the documentation of medical or surgical data.

In this meta-analysis, any of the following literature that met the exclusion criteria were excluded:
1. Reviews, case reports, meeting abstracts, animal trials, or trial registration reports;
2. Full text was unavailable;
3. Unclear or inappropriate definition of exposure/results;
4. Limited information was available for extracting or duplicating data.

Data extraction
Two researchers reviewed each study independently according to the inclusion and exclusion criteria, any ambiguities were reviewed by a third researcher. First, we eliminated duplicate files, filtered the studies by titles and abstracts, and then read the full-text details to filter irrelevant studies. The two researchers recorded with excel spreadsheets and independently extracted data from articles that met the requirements. The specific format is as follows: (1) General characteristics of study: study, year, study type. (2) Intervention: gestation age, the number of participants, dosage. (3) Outcomes.

Quality assessment
The research team used the Newcastle-Ottawa Scale (NOS) to assess the risk of bias in cohort studies, with three factors of patient selection, group comparability, and outcome assessment. Higher scores represent higher quality, and more than 7 out of 9 represent high-quality articles. We also used Jadad scale (ranging from 0 to 5) to evaluate the risk of bias in randomized
controlled trials, including randomized evaluation, blind method of outcome evaluation and description of withdrawal and dropouts. A study with a Jadad score of more than 3 was considered to be of high quality.

**Statistical analysis**

In our study, STATA software version 12.0 (Stata Corp, College Station, TX) was used for analysis. For continuous results, MD and 95% confidence intervals (CI) were used for calculations. For dichotomous results, OR and 95% CI were used for calculations. Heterogeneity was evaluated by $I^2$ statistics. When $I^2 < 50\%$, no heterogeneity was considered to exist. When $I^2 \geq 50\%$, a great heterogeneity was considered. Funnel plot, Begg’s and Egger’s tests were performed to evaluate publication bias. To evaluate the stability of the results, sensitivity analysis of ignoring one study at a time was carried out. $P < 0.05$ was considered to be statistically significant.

**Results**

**Search results**

A total of 408 studies were initially screened by the research team, with 373 remaining after duplicate publications were eliminated by computer. Then, 326 studies were excluded by screening titles and abstracts. Finally, two randomized controlled trials and eight observational studies were considered eligible for inclusion [15–24]. The flowchart depicts the selection procedure for the ten studies (Fig 1). Table 1 demonstrates the characteristics of the included studies.

S3 Table shows the details of the NOS quality assessment. From the Newcastle-Ottawa scale, the quality of the included cohort studies ranged from 7 to 9, indicating that the quality of the studies was fair. The quality of the 2 randomized controlled trials we included was at an intermediate level.

**Meta analysis results**

**The effective rate of 1-3days.** The effective rate of 1-3days was included as an outcome of 5 studies which involved 365 infants. No significant difference was observed between the caffeine group and the aminophylline group regarding the effective rate of 1-3days (OR 1.05, 95% CI: 0.40–2.74, $P = 0.914$). There was significant heterogeneity between these studies, so we performed the randomed-effect model in our study ($I^2 = 51.6\%, P = 0.083$, Fig 2).

**Tachycardia.** Tachycardia was included as an outcome between caffeine citrate and aminophylline in 6 studies which involved 557 preterm infants. In the meta-analysis, we observed that the caffeine group had lower incidence of tachycardia compared with the aminophylline group (OR 0.22, 95% CI: 0.13–0.37, $P < 0.001$). There was no significant heterogeneity among these studies ($I^2 = 0.0\%, P = 0.588$, Fig 3). Thus we conducted the meta-analysis using a fixed-effect model.

**Feeding intolerance.** A total of 4 studies (363 infants) recorded the number of infants with feeding intolerance in the caffeine group and the aminophylline group. Compared with aminophylline, preterm infants treated with caffeine citrate had a lower probability of feeding intolerance (OR 0.40, 95% CI: 0.23–0.70, $P = 0.001$). Heterogeneity among studies was low ($I^2 = 38.6\%, P = 0.181$, Fig 4).

**Hyperglycemia.** Hyperglycemia was included as an outcome between caffeine citrate and aminophylline in 3 studies which involved 343 preterm infants. There was no significant heterogeneity between these studies ($I^2 = 0.0\%, P = 0.617$, Fig 5). However, there was no
significant difference between the caffeine citrate and aminophylline groups in terms of hyperglycemia (OR 0.45, 95%CI: 0.19–1.05, \( P = 0.064 \)).

**Total adverse effects.** Total adverse effects was included as an outcome between caffeine citrate and aminophylline in 4 studies which involved 128 preterm infants. The analysis found that compared with aminophylline, infants in the caffeine group had a lower chance of developing total adverse effects (OR 0.41, 95%CI: 0.17–0.97, \( P = 0.042 \)). And the heterogeneity among studies was low (\( I^2 = 22.4% \), \( P = 0.276 \), [Fig 6](#)).

**Sensitivity and publication bias analysis**
Sensitivity analysis of each indicator showed that the results were reliable and stable. Publication bias was calculated using the funnel plot, and there was no obvious asymmetry. Moreover, no obvious publication bias was detected by Begg’s and Egger’s tests (\( P > 0.05 \)).

**Discussion**
Although methylxanthine has been widely administered in many countries for the treatment of AOP, the choice between caffeine and aminophylline is still controversial. It is well known that caffeine has a wider effectiveness as well as less adverse effects than aminophylline, and does not require routine blood concentration measurements [25]. But the present findings
reported that there is no difference between caffeine and aminophylline in terms of incidence apneic, bradycardic or hypoxemic [26]. What’s more, aminophylline is effective in improving the renal function of asphyxiated neonates [27]. Therefore, our meta-analyses aimed to assess the comparative efficacy and safety of caffeine and aminophylline in the treatment of AOP. The results indicated that caffeine was as effective as aminophylline in terms of treating AOP, the occurrence of tachycardia and feeding intolerance in the caffeine group was clearly less than that in the aminophylline group. But the rates of hyperglycemia were similar between the caffeine and aminophylline groups.

### Table 1. Characteristics of included studies.

| Study      | Year | Study type | Gestation age (weeks) | Participants | Dosage | Outcomes | NOS/JS |
|------------|------|------------|-----------------------|--------------|--------|----------|--------|
| Lin        | 2022 | Cohort study | 30.08 ± 2.73 | 48 | iv, the loading dose was 20 mg/kg, followed by a maintenance dosage of 5 mg/kg/dose once per day. | iv, a first dose of 5 mg/kg followed by a maintenance dose of 3 mg/kg/day divided into three doses a day | 2 | 7 |
| Zhang      | 2020 | Cohort study | 29.78±1.42 | 77 | iv, at a first dose of 20 mg/kg followed by a maintenance dose of 10 mg/kg per day | iv, at a first dose of 5 mg/kg followed by a maintenance dose of 2.5 mg/kg twice per day | 1 | 7 |
| Nagasato   | 2018 | Cohort study | 23.9–34.1 | 34 | iv, a maintenance dose of 6.4 mg/kg/d iv for 47 days | iv, a maintenance dose of 3.2 mg/kg/d for 42 days | 10 | 7 |
| Shivakumar | 2017 | Cohort study | 29.4±2 | 77 | iv or oral, the loading dose was 20 mg/kg and the maintenance dose of 5 mg/kg 24 hourly | inj, the loading dose 5 mg/kg and maintenance dose of 1.5 mg/kg 8 hourly | 10 | 8 |
| Xu         | 2014 | Cohort study | 26–36 | 65 | iv, at a first dose of 20 mg/kg followed by a maintenance dose of 5 mg/kg per day | iv, at a first dose of 5 mg/kg followed by a maintenance dose of 2 mg/kg 12 hourly | 10 | 7 |
| Skouroliakou | 2009 | Cohort study | 30.4±1.9 | 33 | the loading dose was 20 mg/kg given intravenously over 30 min and the maintenance doses was 5 mg/kg per day | iv, the loading dose was 4.8 mg/kg and the maintenance doses was 2 mg/kg every 12 h | 10 | 9 |
| Larsen     | 1995 | Cohort study | 25–33 | 82 | iv loading dose of caffeine citrate 20.2 mg/kg followed by a maintenance dose of 2.5 mg/kg iv or by a gastric baby feeding tube twice a day for 10 days. | the loading dose of 6.2 mg/kg followed by a maintenance dose of 3.1 mg/kg iv or by a gastric baby feeding tube twice a day for 10 days. | 10 | 9 |
| Scanlon    | 1992 | Cohort study | 28.7±1.2 | 16 | ivgtt, at a first dose of 25 mg/kg followed by a maintenance dose of 6 mg/kg per day | ivgtt, at a first dose of 7.5 mg/kg followed by a maintenance dose of 3 mg/kg 8 hourly | 10 | 7 |
| Bairam     | 1987 | RCT         | 30.0±1.5 | 10 | ivgtt, at a first dose of 10 mg/kg followed by a maintenance dose of 1.25 mg/kg 12 hourly | ivgtt, at a first dose of 6 mg/kg followed by a maintenance dose of 2 mg/kg 12 hourly | 10 | 3 |
| Brouard    | 1985 | RCT         | 30.5±0.7 | 8 | ivgtt, at a first dose of 20 mg/kg followed by a maintenance dose of 5 mg/kg 24 hourly | ivgtt, at a first dose of 5.5 mg/kg followed by a maintenance dose of 0.5–2.5 mg/kg 8 hourly | 10 | 3 |

Notes: ① the effective rate of 1-3 days ② tachycardia ③ feeding intolerance ④ hyperglycemia ⑤ total adverse effects.

https://doi.org/10.1371/journal.pone.0274882.t001
We believe that caffeine and aminophylline treatments are equivalent effective in reducing apnea of prematurity, which has been confirmed in several independent studies [28, 29]. Steer similarly concluded that in the short term, caffeine was as effective as aminophylline in reducing the incidence of apnea and was better tolerated and easier to administer. These are related to the mechanism of methylxanthine, caffeine and aminophylline are both central nervous...

Fig 2. Forest plot of showing the effects of caffeine vs aminophylline on the effective rate of 1–3 days. 
https://doi.org/10.1371/journal.pone.0274882.g002

Fig 3. Forest plot of showing the effects of caffeine vs aminophylline on tachycardia. 
https://doi.org/10.1371/journal.pone.0274882.g003
system stimulants. They have the same effect of increasing diaphragm contractility and lowering hypercapnia susceptibility threshold [30]. Some studies have further shown that prophylactic use of caffeine for preterm infants at risk of apnea reduced the duration of mechanical ventilation [31]. Borszewska-Kornacka [32] found that preventive use of caffeine within 24 hours after birth can reduce the use of invasive ventilator and the incidence of IVH and PDA compared with therapeutic use of caffeine. However, whether caffeine should be used
prophylactically in all preterm infants remains controversial [33]. It is necessary to conduct a definitive study to illustrate the comparative effects of prophylactic and therapeutic caffeine. Tachycardia is one of the most common acute adverse reactions of methylxanthines. We demonstrated a lower incidence of tachycardia in infants treated with caffeine compared with aminophylline. Our result is consistent with those obtained by Alhersh et al. [34]. One possible interpretation of the result is that caffeine is more active than aminophylline in stimulating central nervous system, but less active in stimulating heart [35]. In addition, aminophylline contains phenethyl alcohol, which could directly stimulate the respiratory center to increase its sensitivity to carbon dioxide, leading to an increase in respiratory rate, thus causing tachycardia in preterm infants. Ultimately, aminophylline exhibits unique toxicokinetics in premature infants with sinus tachycardia due to the great developmental differences between neonates and adults [36]. As a result, caffeine is superior to aminophylline in terms of the risk of tachycardia.

Our study showed that caffeine significantly reduced the incidence of feeding intolerance compared with aminophylline treatment, the result is indeed in line with research of Rostas et al. [4]. Analyzing the possible causes, the serum half-life of aminophylline ranges from 24.7 to 36.5 h, while caffeine’s serum half-life is 101 h in preterm infants [18]. Caffeine has a longer elimination half-life, allowing for once-daily dosing. Therefore, administration once a day has less effect on the upper gastrointestinal tract than administration multiple times a day. Another reason could be that caffeine is absorbed more rapidly by gastrointestinal tract than aminophylline, with little or no first-pass metabolism [37]. In addition, the dosage of caffeine therapy can be challenging because of the limited hepatic, renal, and respiratory function of preterm infants. A previous study has shown that high doses of caffeine lead to the decrease of mesenteric blood flow and serious feeding intolerance of caffeine generally appears at concentrations >60 mg/L [30]. But chen [38] found that higher doses of caffeine (10–20 mg/kg daily) were more effective than lower doses (5–10 mg/kg daily) and that higher doses were more closely associated with withdrawal from the ventilator. Definitive recommendations on the optimal
caffeine dose cannot be given due to our research not making a specific distinction between drug doses, future research is necessary to elucidate the effects of different maintenance doses of caffeine in the treatment of AOP.

Furthermore, our study shows the risk of hyperglycemia of caffeine is similar to that of aminophylline. Our results are different from those of Hady et al., who found caffeine has little risk of hyperglycemia, which is associated with its hydrophobicity and distributes rapidly without tissue accumulation [35]. The discrepancy between our study and others may be due to the insufficient number of studies we included on measures of hyperglycemia. More well-designed and larger sample studies should be carried out to examine and expand the conclusions.

Some literature did not describe specific types of adverse reactions, but summarized all the adverse reactions in general, so we further discussed the risk of total adverse effects. The results of our meta-analysis indicated that the total adverse effects rate of caffeine in the treatment of apnea is lower than that of aminophylline. It may be related to the narrow safe range of aminophylline concentration in blood. Ye [39] have also suggested that excessive serum concentration of aminophylline was related to an increased risk of adverse effects. Patients with aminophylline blood concentration >20 μg/ml may have symptoms such as tachycardia and arrhythmia, while patients with aminophylline blood concentration >40 μg/ml may have symptoms such as fever, dehydration, convulsion and even death. However, caffeine has a wide range of safety, with serum levels of 3–84 mg/L considered therapeutic and safe [40]. Furthermore, the plasma concentration fluctuation of caffeine in neonates is smaller than aminophylline, caffeine has greater central nervous system penetration, and does not produce fluctuation of cerebral blood flow [41]. Liu et al. [42] has shown that caffeine may have a direct long-term neuroprotective effect on the developing brain. Mürner-Lavanchy et al. [43] also reported that caffeine therapy for apnea of prematurity improved visuomotor, visuoperceptual, and visuospatial abilities at age 11 years. General intelligence, attention, and behavior were not adversely affected by caffeine. In order to truly prove the safety of caffeine citrate, more long-term follow-up studies are necessary.

Our meta-analysis differs from other analyses in that it not only compares the effectiveness of caffeine and aminophylline, but also evaluates their safety in preterm infants. Despite the overwhelming evidence that caffeine is safer and more effective than aminophylline, and the resulting widespread use in developed countries. However, the use of caffeine therapy remains alarmingly low in sub-Saharan Africa, greater efforts are needed to ensure broader utilization of caffeine therapeutic regimens.

Limitation
It is worth noting that our meta-analysis still has many limitations. First, limited number of RCTs were retrieved, and we included relevant non-RCT studies to expand the total sample size. The limited number of RCTs resulted in a smaller randomized sample size, which may have biased the results. Moreover, the information on long-term outcomes of methylxanthines in our included studies is still insufficient and large-scale trials should be conducted in the future to evaluate the potential long-term adverse outcomes in clinical practice.

Conclusion
In summary, evidence has shown that caffeine and aminophylline are equally effective for apnea of prematurity but caffeine has fewer adverse effects on infants. For these reasons, we recommend caffeine as an effective and feasible first-line treatment for apnea in preterm infants. We believe it will help update the available evidence on the benefits and harms of
methylxanthine treatment for AOP, thus enabling researchers and clinicians to make the proper choice for the treatment of AOP.

Supporting information
S1 Table. PRISMA checklist.
(DoCX)
S2 Table. Search strategy.
(DoCX)
S3 Table. Assessment of methodological quality by NOS.
(DoCX)

Author Contributions
Conceptualization: Yiqun Miao, Yun Zhou, Shuliang Zhao, Huimin Jiang.
Data curation: Yiqun Miao, Yun Zhou, Shuliang Zhao, Wenwen Liu, Yanan Li.
Formal analysis: Yiqun Miao, Yun Zhou, Shuliang Zhao.
Funding acquisition: Aihua Wang, Yuanyuan Zhang.
Investigation: Yiqun Miao, Yun Zhou, Shuliang Zhao, Wenwen Liu, Huimin Jiang.
Methodology: Yiqun Miao, Yun Zhou, Shuliang Zhao, Wenwen Liu, Yanan Li, Huimin Jiang.
Project administration: Aihua Wang, Yuanyuan Zhang.
Resources: Aihua Wang.
Software: Yiqun Miao, Yanan Li.
Validation: Shuliang Zhao, Wenwen Liu, Aihua Wang, Yuanyuan Zhang.
Writing – original draft: Yiqun Miao, Yun Zhou.
Writing – review & editing: Yiqun Miao, Aihua Wang, Yuanyuan Zhang.

References
1. Kondamudi NP, Krata L, Wilt AS. Infant Apnea. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2022; StatPearls Publishing LLC.; 2022.
2. Seppä-Moilanen M, Andersson S, Kirjavainen T. Spontaneous and apnea arousals from sleep in pre-term infants. Pediatric research. 2021; 89(5):1261–7. https://doi.org/10.1038/s41390-020-1068-2 PMID: 32682326
3. Montenegro BL, Amberson M, Veit L, Freiberger C, Dukhovny D, Rhein LM. Economics of Home Monitoring for Apnea in Late Preterm Infants. Respiratory care. 2017; 62(1):42–8. https://doi.org/10.4187/respcare.04954 PMID: 28003553
4. Rostas SE, McPherson C. Caffeine Therapy in Preterm Infants: The Dose (and Timing) Make the Medicine. Neonatal network: NN. 2019; 38(6):365–74. https://doi.org/10.1891/0730-0832.38.6.365 PMID: 31712401
5. Bancalari E. Current management of apnea in premature infants: is caffeine the magic bullet? Early human development. 2014; 90 Suppl 2:S1–2. https://doi.org/10.1016/S0378-3782(14)50001-1 PMID: 25220117
6. Pergolizzi J, Kraus A, Magnusson P, Breve F, Mitchell K, Raffa R, et al. Treating Apnea of Prematurity. Cureus. 2022; 14(1):e21783. https://doi.org/10.7759/cureus.21783 PMID: 35215853
7. Alur P, Bollampalli V, Bell T, Hussain N, Lisa J. Serum caffeine concentrations and short-term outcomes in premature infants of <29 weeks of gestation. Journal of perinatology: official journal of the California Perinatal Association. 2015; 35(6):434–8. https://doi.org/10.1038/jp.2014.226 PMID: 25521559
8. Shrestha B, Jawa G. Caffeine citrate—Is it a silver bullet in neonatology? Pediatrics and neonatology. 2017; 58(5):391–7. https://doi.org/10.1016/j.pedneo.2016.10.003 PMID: 28446386

9. Atik A, Harding R, De Matteo R, Kondos-Devic D, Cheong J, Doyle LW, et al. Caffeine for apnea of prematurity: Effects on the developing brain. Neurotoxicology. 2017; 58:94–102. https://doi.org/10.1016/j.neuro.2016.11.012 PMID: 27899304

10. Abu-Shaweesh JM, Martin RJ. Caffeine use in the neonatal intensive care unit. Seminars in fetal & neonatal medicine. 2017; 22(5):342–7. https://doi.org/10.1016/j.siny.2017.07.011 PMID: 28801767

11. Schmidt B, Roberts RS, Davis P, Doyle LW, Barrington KJ, Ohlsson A, et al. Caffeine therapy for apnea of prematurity. The New England journal of medicine. 2006; 354(20):2112–21. https://doi.org/10.1056/NEJMoa054065 PMID: 16707748

12. Mueni E, Opiyo N, English M. Caffeine for the management of apnea in preterm infants. International journal of health. 2009; 1(2):190–5. https://doi.org/10.1016/j.inhe.2009.09.005 PMID: 20676238

13. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS medicine. 2009; 6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097 PMID: 19621072

14. Erenberg A, Leff RD, Haack DG, Mosdell KW, Hicks GM, Wynne BA. Caffeine citrate for the treatment of apnea of prematurity: a double-blind, placebo-controlled study. Pharmacotherapy. 2000; 20(6):644–52. https://doi.org/10.1592/phco.20.7.644.35167 PMID: 10853619

15. Bairam A, Boutroy MJ, Badonnel Y, Vert P. Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant. The Journal of pediatrics. 1987; 110(4):636–9. https://doi.org/10.1016/s0022-3476(87)80569-3 PMID: 3559816

16. Brouard C, Moriette G, Murat I, Flouvat B, Pajot N, Walti H, et al. Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. American journal of diseases of children (1960). 1985; 139(7):698–700. https://doi.org/10.1001/archpedi.1985.0214009060028 PMID: 4014092

17. Larsen PB, Brendstrup L, Skov L, Flachs H. Aminophylline versus caffeine citrate for apnea and bradycardia prophylaxis in premature neonates. Acta paediatrica. 1995; 84(4):360–4. https://doi.org/10.1111/j.1651-2227.1995.tb13649.x PMID: 7795341

18. Lin YC, Tan YL, Yen TA, Chen CY, Tsao PN, Chou HC. Specific Premature Groups Have Better Benefits When Treating Apnea With Caffeine Than Aminophylline/Theophylline. Frontiers in pediatrics. 2022; 10:817624. https://doi.org/10.3389/fped.2022.817624 PMID: 35281246

19. Nagasato A, Nakamura M, Kamimura H. [Comparative Study of the Efficacy and Safety of Caffeine and Aminophylline for the Treatment of Apnea in Preterm Infants]. Yakugaku zasshi. 2018; 139(2):237–42. https://doi.org/10.1248/yakushi.17-00144 PMID: 29386437

20. Scanlon JE, Chin KC, Morgan ME, Durbin GM, Hale KA, Brown SS. Caffeine or theophylline for neonatal apnoea? Archives of disease in childhood. 1992; 67(4 Spec No):425–8. https://doi.org/10.1136/adc.67.4_spec_no.425 PMID: 1586184

21. Shivakumar M, Jayashree P, Najih M, Lewis LES, Bhat YR, Kamath A, et al. Comparative Efficacy and Safety of Caffeine and Aminophylline for Apnea of Prematurity in Preterm (<34 weeks) Neonates: A Randomized Controlled Trial. Indian pediatrics. 2017; 54(4):279–83. https://doi.org/10.1007/s13312-017-1088-0 PMID: 28474588

22. Skouraliakou M, Bacopoulou F, Markantonis SL. Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. Journal of paediatrics and child health. 2009; 45(10):587–92. https://doi.org/10.1111/j.1440-1754.2009.01570.x PMID: 19751376

23. Xu JL, Wang RQ, Chen DM. Comparison of caffeine citrate and aminophylline for treating primary apnea in premature infants[J]. Chinese journal of contemporary pediatrics, 2014, 16(11):1129–32. (In Chinese).

24. Zhang CY, Liu DJ, Hua SD, Guo S, Li XY, Zhang B, et al. Caffeine versus aminophylline in combination with oxygen therapy for apnea of prematurity: A retrospective cohort study. Exp Ther Med. 2020; 20(5):46. https://doi.org/10.3892/etm.2020.9175 PMID: 32952637

25. Schmidt B. Methyloxanthine therapy for apnea of prematurity: evaluation of treatment benefits and risks at age 5 years in the international Caffeine for Apnea of Prematurity (CAP) trial. Biology of the neonate. 2005; 88(3):208–13. https://doi.org/10.1159/000087584 PMID: 16210843

26. Henderson-Smart DJ, Steer PA. Caffeine versus theophylline for apnea in preterm infants. The Cochrane database of systematic reviews. 2010;1:Cd000273. https://doi.org/10.1002/14651858.CD000273.pub2 PMID: 20091506

27. Bellos I, Pandita A, Yachha M. Effectiveness of theophylline administration in neonates with perinatal asphyxia: a meta-analysis. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies,
28. Steer PA, Henderson-Smart DJ. Caffeine versus theophylline for apnea in preterm infants. The Cochrane database of systematic reviews. 2000;(2):Cd000273. https://doi.org/10.1002/14651858.CD000273 PMID: 10796190

29. Dobson NR, Hunt CE. Caffeine: an evidence-based success story in VLBW pharmacotherapy. Pediatric research. 2018; 84(3):333–40. https://doi.org/10.1038/s41390-018-0089-6 PMID: 29983414

30. Eichenwald EC. Apnea of Prematurity. Pediatrics. 2016; 137(1). https://doi.org/10.1542/peds.2015-3757 PMID: 26628729

31. Hendry-Smart DJ, De Paoli AG. Prophylactic methylxanthine for prevention of apnoea in preterm infants. The Cochrane database of systematic reviews. 2010; 2010(12):Cd000432. https://doi.org/10.1002/14651858.CD000432.pub2 PMID: 21154344

32. Borszewska-Kornacka MK, Hożejowski R, Rutkowska M, Lauterbach R. Shifting the boundaries for early caffeine initiation in neonatal practice: Results of a prospective, multicenter study on very preterm infants with respiratory distress syndrome. PLoS One. 2017; 12(12):e0189152. https://doi.org/10.1371/journal.pone.0189152 PMID: 29261723

33. Eichenwald EC. National and international guidelines for neonatal caffeine use: Are they evidence-based? Seminars in fetal & neonatal medicine. 2020; 25(6):101177. https://doi.org/10.1016/j.siny.2020.101177 PMID: 33214064

34. Alhersh E, Abushanab D, Al-Shaibi S, Al-Badryeh D. Caffeine for the Treatment of Apnea in the Neonatal Intensive Care Unit: A Systematic Overview of Meta-Analyses. Paediatric drugs. 2020; 16(2):169–77. https://doi.org/10.1007/s40272-013-0063-z PMID: 24399614

35. Chen J, Jin L, Chen X. Efficacy and Safety of Different Maintenance Doses of Caffeine Citrate for Treatment of Apnea in Premature Infants: A Systematic Review and Meta-Analysis. Biomed research international. 2018; 2018:9061234. https://doi.org/10.1155/2018/9061234 PMID: 30671477

36. Rietbrock K, Yu T, Khorshidzad F, Spigarelli MG, Sherwin CM. Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity: A systematic review. Paediatric drugs. 2014; 16(2):169–77. https://doi.org/10.1007/s40272-013-0063-z PMID: 24399614

37. Johnson PJ. Caffeine citrate therapy for apnea of prematurity. Neonatal Netw. 2011; 30(6):408–12. https://doi.org/10.1891/0730-0832.30.6.408 PMID: 22052121

38. Chen J, Jin L, Chen X. Efficacy and Safety of Different Maintenance Doses of Caffeine Citrate for Treatment of Apnea in Premature Infants: A Systematic Review and Meta-Analysis. Biomed research international. 2018; 2018:9061234. https://doi.org/10.1155/2018/9061234 PMID: 30671477

39. Ye C, Miao C, Yu L, Dong Z, Zhang J, Mao Y, et al. Factors affecting the efficacy and safety of aminophylline in treatment of apnea of prematurity in neonatal intensive care unit. Pediatrics and neonatology. 2019; 60(1):43–9. https://doi.org/10.1016/j.pedneo.2018.03.008 PMID: 29673564

40. Aranda JV, Turmen T. Methylxanthines in apnea of prematurity. Clinics in perinatology. 1979; 6(1):87–108. PMID: 383366

41. Comer AM, Perry CM, Figgitt DP. Caffeine citrate: a review of its use in apnoea of prematurity. Paediatric drugs. 2001; 3(1):61–79. https://doi.org/10.2165/00128072-200103010-00005 PMID: 11220406

42. Liu S, Zhang X, Liu Y, Yuan X, Yang L, Zhang R, et al. Early application of caffeine improves white matter development in very preterm infants. Respir Physiol Neurobiol. 2020; 281:103495. https://doi.org/10.1016/j.resp.2020.103495 PMID: 32673970

43. Mürer-Lavanchy IM, Doyle LW, Schmidt B, Roberts RS, Asztalos EV, Costantini L, et al. Neurobehavioral Outcomes 11 Years After Neonatal Caffeine Therapy for Apnea of Prematurity. Pediatrics. 2018; 141(5). https://doi.org/10.1542/peds.2017-4047 PMID: 29943070